GS-441524 is an active metabolite of Remdesivir (GS-5734; Veklury) which is an FDA approved drug for treating the 2019-nCoV (COVID-19 pandemic, CoronaVirus) infections. GS-441524 is a novel, potent FIP (feline infectious peritonitis) virus inhibitor with an EC50 of 0.78 μM. GS-441524 potently FIP virus in tissue culture and experimental cat infection studies. GS-441524 is a molecular precursor to a pharmacologically active nucleoside triphosphate molecule. These analogs act as an alternative substrate and RNA-chain terminator of viral RNA dependent RNA polymerase. GS-441524 was non-toxic in feline cells at concentrations as high as 100 uM and effectively inhibited FIPV replication in cultured CRFK cells and in naturally infected feline peritoneal macrophages at concentrations as low as 1 uM.

纯度：≥98%

CAS：2378280-82-9